HSBC Mutual Fund has announced an increase in its shareholding in Thyrocare Technologies Limited, now exceeding the 5% threshold. This disclosure, made in accordance with SEBI regulations, details the fund’s aggregate shareholding and voting rights in the target company. The fund’s holdings now stand at 6.63% post-acquisition, reflecting a significant investment update.
HSBC Mutual Fund Boosts Thyrocare Stake
HSBC Mutual Fund, acting as the investment manager, has officially disclosed a material change in its shareholding in Thyrocare Technologies Limited. The fund’s aggregate shareholding and voting rights in the target company have now surpassed the 5% mark, as per the requirements of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Key Holding Details
The disclosure indicates that prior to the recent acquisition, HSBC Mutual Fund held 75,57,935 shares, representing 4.75% of the total share capital. Following the acquisition of an additional 29,99,731 shares, the fund’s total holding now amounts to 1,05,57,666 shares, which translates to 6.63% of the total share capital and voting rights in Thyrocare Technologies Limited. This acquisition was made through Shares Purchased on the open market.
The total equity share capital of Thyrocare Technologies Limited before and after this acquisition remains unchanged at 15,91,65,315 shares. The date of acquisition for this stake increase was reported as August 13, 2026, with the disclosure being made on August 17, 2026.
Source: BSE
